Skip to content
ClinCalc Pro
Menu
H1 antihistamine (topical)

Azelastine hydrochloride

Brand names: Rhinolast, Optilast, Dymista (with fluticasone)

Azelastine hydrochloride is a topical second-generation antihistamine used in nasal spray and eye drop formulations for allergic rhinitis and allergic conjunctivitis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively antagonises peripheral histamine H1 receptors and stabilises mast cells, reducing the histamine-driven allergic response in the nasal and ocular mucosa.

Prescribing in practice

  • Applied topically it acts locally with rapid onset and limited systemic absorption, so systemic antihistamine effects are uncommon at recommended use.
  • A bitter or altered taste is a characteristic and common adverse effect of the nasal spray, which may affect adherence.
  • Mild local irritation, nasal stinging or transient eye irritation may occur with the respective formulations.

Monitoring

No routine laboratory monitoring is required; assess symptom control and local tolerability at review.

Counselling the patient

  • A bitter taste after using the nasal spray is common and can be reduced by keeping the head tilted forward and not sniffing hard.
  • Use regularly during the allergy season for best effect.
  • Tell your team if local irritation is troublesome or symptoms are not controlled.

Evidence & guidelines

Topical antihistamines such as azelastine are established options for allergic rhinitis and conjunctivitis, providing rapid local symptom relief in line with allergy guidance.

Reference: BSACI; NICE CKS Allergic rhinitis; RCOphth; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.